Fluicell AB

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

-49.48%

Rev. gr., 5y

-5.66%

Revenues

-44.31%

Net income

-16m

L-41.59%

CFO

-16m

L-42.45%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.

URL

https://fluicell.com/

IPO date

Apr 18, 2018

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT